You are here:

lurasidone (Latuda)

Advice

following a full submission:

lurasidone (Latuda®) is accepted for restricted use within NHS Scotland.

Indication under review: For the treatment of schizophrenia in adults aged 18 years and over.

SMC Restriction: as an alternative treatment option in patients in whom it is important to avoid weight gain and metabolic adverse effects.

Lurasidone demonstrated benefit over placebo in mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after six weeks of treatment and was non-inferior to another second generation antipsychotic medicine for time to relapse over 12 months.
 

Drug Details

Drug Name: lurasidone (Latuda)
SMC Drug ID: 994/14
Manufacturer: Sunovion
Indication: For the treatment of schizophrenia in adults aged 18 years and over.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 October 2014

Back